Cardiovascular Research

Perifoveal Choriocapillaris Flow Deficits Associated With Cerebrospinal Fluid Aβ42/tau in Presymptomatic Alzheimer's Disease.

Authors: Jane W Chan|||Giulia Corradetti|||Xiaomeng Wu|||Natalie Astraea|||Xianghong Arakaki|||Alfred N Fonteh|||Astrid M Suchy-Dicey|||SriniVas Sadda

Affiliations: + Expand

Abstract

This study investigated the association between swept-source OCTA (SS-OCTA) choriocapillaris flow deficit percentage (CC FD%) and cerebrospinal fluid (CSF) biomarkers in presymptomatic Alzheimer's disease (AD).

---

Chemical List

Amyloid beta-Peptides|||tau Proteins|||amyloid beta-protein (1-42)|||Peptide Fragments|||Biomarkers

---

Reference List

Farkas E, Luiten PG. Cerebral microvascular pathology in aging and Alzheimer's disease. 2001; 64: 575–611. ||| Biffi E, Turple Z, Chung J, Biffi A. Retinal biomarkers of cerebral small vessel disease: a systematic review. . 2022; 17(4): e0266974. ||| Patton N, Aslam T, Macgillivray T, Pattie A, Deary IJ, Dhillon B. Retinal vascular image analysis as a potential screening tool for cerebrovascular disease: a rationale based on homology between cerebral and retinal microvasculatures. 2005; 206: 319–348. ||| Zlokovic BV. Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders. . 2011; 12(12): 723–738. ||| Tiosano L, Corradetti G, Sadda SR. Progression of choriocapillaris flow deficits in clinically stable intermediate age-related macular degeneration. . 2021; 35: 2991–2998. ||| Corradetti G, Oncel D, Kadomoto S, et al.. Choriocapillaris and retinal vascular alterations in presymptomatic Alzheimer's disease. . 2024; 65: 47.||| Harrington MG, Chiang J, Pogoda JM, et al.. Executive function changes before memory in preclinical Alzheimer's pathology: a prospective, cross-sectional, case control study. . 2013; 8: e79378. ||| Bangen KJ, Nation DA, Delano-Wood L, et al.. Aggregate effects of vascular risk factors on cerebrovascular changes in autopsy-confirmed Alzheimer's disease. . 2015; 11: 394–403.e391. ||| Nation DA, Delano-Wood L, Bangen KJ, et al.. Antemortem pulse pressure elevation predicts cerebrovascular disease in autopsy-confirmed Alzheimer's disease. . 2012; 30: 595–603. ||| Wang RK, An L, Francis P, Wilson DJ. Depth-resolved imaging of capillary networks in retina and choroid using ultrahigh sensitive optical microangiography. . 2010; 35: 1467–1469. ||| Kar D, Amjad M, Corradetti G, et al.. Choriocapillaris impairment, visual function, and distance to fovea in aging and age-related macular degeneration: ALSTAR2 baseline. . 2024. 65(8): 40.||| Corradetti G, Oncel D, Kadomoto S, et al.. Choriocapillaris and retinal vascular alterations in presymptomatic Alzheimer's disease. . 2024; 65: 47.||| Alagorie AR, Corradetti G, Byon I, et al.. Impact of slab selection on the relationship between choriocapillaris flow deficits and enlargement rate of geographic atrophy. . 2024; 38: 847–852. ||| Fogel Levin M, Santina A, Corradetti G, et al.. Pentosan polysulfate sodium-associated maculopathy: early detection using OCT angiography and choriocapillaris flow deficit analysis. . 2022; 244: 38–47. ||| Tiosano L, Corradetti G, Sadda SR. Progression of choriocapillaris flow deficits in clinically stable intermediate age-related macular degeneration. . 2021; 35: 2991–2998. ||| Corvi F, Corradetti G, Tiosano L, et al.. Topography of choriocapillaris flow deficit predicts development of neovascularization or atrophy in age-related macular degeneration. . 2021; 259: 2887–2895. ||| Koronyo Y, Biggs D, Barron E, et al.. Retinal amyloid pathology and proof-of-concept imaging trial in Alzheimer's disease. . 2017; 2(16): e93621. ||| Koronyo-Hamaoui M, Koronyo Y, Ljubimov AV, et al.. Identification of amyloid plaques in retinas from Alzheimer's patients and noninvasive in vivo optical imaging of retinal plaques in a mouse model. . 2011; 54(Suppl 1): S204–217. ||| Tsai Y, Lu B, Ljubimov AV, et al.. Ocular changes in TgF344-AD rat model of Alzheimer's disease. . 2014; 55(1): 523–534. ||| Mirzaei M, Pushpitha K, Deng L, et al.. Upregulation of proteolytic pathways and altered protein biosynthesis underlie retinal pathology in a mouse model of Alzheimer's disease. . 2019; 56: 6017–6034. ||| Kwapong WR, Tang F, Liu P, et al.. Choriocapillaris reduction accurately discriminates against early-onset Alzheimer's disease. . 2024; 20: 4185–4198. ||| Zhang S, Kwapong WR, Yang T, et al.. Choriocapillaris changes are correlated with disease duration and MoCA score in early-onset dementia. . 2021; 13: 656750. ||| Mattsson-Carlgren N, Andersson E, Janelidze S, et al.. Abeta deposition is associated with increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's disease. . 2020; 6: eaaz2387. ||| Montoliu-Gaya L, Benedet AL, Tissot C, et al.. Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies. . 2023; 3: 661–669. ||| Therriault J, Vermeiren M, Servaes S, et al.. Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography. . 2023; 80: 188–199. ||| Jack CR, Wiste HJ, Algeciras-Schimnich A, et al.. Predicting amyloid PET and tau PET stages with plasma biomarkers. . 2023; 146: 2029–2044. ||| Barthelemy NR, Salvado G, Schindler SE, et al.. Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests. . 2024; 30: 1085–1095. ||| Zhang Y, Bi K, Zhou L, et al.. Advances in blood biomarkers for Alzheimer's disease: ultra-sensitive detection technologies and impact on clinical diagnosis. . 2024; 14: 85–102.